Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

IOV-4001

Generic Name: IOV-4001

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Phase 1

Recruiting

Posted: 2022/05/04

Sponsor:Iovance Biotherapeut...

ID:NCT05361174

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Iovance Biotherapeutics Advances Melanoma Treatment Portfolio with Amtagvi Launch and Pipeline Expansion

4 months ago

Iovance Biotherapeutics reports encouraging initial sales of $58.6 million for Amtagvi in Q3, while advancing its TIL therapy pipeline. The company is expanding its clinical programs into frontline melanoma and lung cancer, alongside development of next-generation TIL therapy IOV-4001, despite facing manufacturing cost challenges.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy